Hand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after the onset of illness from HFMD patients infected with enterovirus A71 (EV-A71), coxsackievirus A (CVA) 6, CVA10, and CVA16 to study cross neutralization. For homotypic viruses, seropositivity increased from <60% at enrollment to 97%-100% at follow-up, corresponding to seroconversion rates of 57%-93%. Seroconversion for heterotypic viruses was recorded in only 3%-23% of patients. All plasma samples from patients infected with EV-A71 subgenogroup B5 could neutralize the emerging EV-A71 subgenogroup C4. Collectively, our results support previous reports about the potential benefit of EV-A71 vaccine but highlight the necessity of multivalent vaccines to control HFMD.

中文翻译：

---

中和手足口病患者肠道病毒抗体。

手足口病 (HFMD) 是一种具有大流行潜力的新兴传染病。了解其病原体中的中和抗体反应对于疫苗开发和流行病学研究至关重要。我们使用从感染肠道病毒 A71 (EV-A71)、柯萨奇病毒 A (CVA) 6、CVA10 和 CVA16 的手足口病患者入组时和发病后 7 天收集的 120 份配对血浆样本来研究交叉中和作用。对于同型病毒，血清阳性率从入组时的 <60% 增加到随访时的 97%-100%，对应于 57%-93% 的血清转化率。仅 3%-23% 的患者记录了异型病毒的血清转化。来自感染 EV-A71 亚基因组 B5 的患者的所有血浆样本都可以中和新出现的 EV-A71 亚基因组 C4。集体，